161 related articles for article (PubMed ID: 24412910)
1. Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease.
Jolles S; Borte M; Nelson RP; Rojavin M; Bexon M; Lawo JP; Wasserman RL
Clin Immunol; 2014 Feb; 150(2):161-9. PubMed ID: 24412910
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
Jolles S; Bernatowska E; de Gracia J; Borte M; Cristea V; Peter HH; Belohradsky BH; Wahn V; Neufang-Hüber J; Zenker O; Grimbacher B
Clin Immunol; 2011 Oct; 141(1):90-102. PubMed ID: 21705277
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.
Niebur HB; Duff CM; Shear GF; Nguyen D; Alberdi TK; Dorsey MJ; Sleasman JW
Clin Exp Immunol; 2015 Sep; 181(3):441-50. PubMed ID: 25761372
[TBL] [Abstract][Full Text] [Related]
4. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
[TBL] [Abstract][Full Text] [Related]
5. Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies.
Mallick R; Jolles S; Kanegane H; Agbor-Tarh D; Rojavin M
J Clin Immunol; 2018 Nov; 38(8):886-897. PubMed ID: 30465179
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.
Stein MR; Koterba A; Rodden L; Berger M
Postgrad Med; 2011 Sep; 123(5):186-93. PubMed ID: 21904101
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.
Jolles S; Sleasman JW
Adv Ther; 2011 Jul; 28(7):521-33. PubMed ID: 21681653
[TBL] [Abstract][Full Text] [Related]
8. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.
Berger M; Murphy E; Riley P; Bergman GE;
South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467
[TBL] [Abstract][Full Text] [Related]
9. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.
Jolles S; Rojavin MA; Lawo JP; Nelson R; Wasserman RL; Borte M; Tortorici MA; Imai K; Kanegane H
J Clin Immunol; 2018 Nov; 38(8):864-875. PubMed ID: 30415311
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.
Kanegane H; Imai K; Yamada M; Takada H; Ariga T; Bexon M; Rojavin M; Hu W; Kobayashi M; Lawo JP; Nonoyama S; Hara T; Miyawaki T
J Clin Immunol; 2014 Feb; 34(2):204-11. PubMed ID: 24504846
[TBL] [Abstract][Full Text] [Related]
12. Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin.
Milota T; Bloomfield M; Kralickova P; Jilek D; Novak V; Litzman J; Posova H; Mrazova L; Poloniova J; Prucha M; Rozsival P; Rauschova V; Philipp G; Sediva A
Clin Ther; 2019 Nov; 41(11):2231-2238. PubMed ID: 31564514
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis.
Shapiro RS
Ann Allergy Asthma Immunol; 2013 Jul; 111(1):51-5. PubMed ID: 23806460
[TBL] [Abstract][Full Text] [Related]
14. Hizentra for the treatment of primary immunodeficiency.
Wasserman RL
Expert Rev Clin Immunol; 2014 Oct; 10(10):1293-307. PubMed ID: 25182658
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency.
Borte M; Pac M; Serban M; Gonzalez-Quevedo T; Grimbacher B; Jolles S; Zenker O; Neufang-Hueber J; Belohradsky B
J Clin Immunol; 2011 Oct; 31(5):752-61. PubMed ID: 21674136
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
Wasserman RL; Melamed I; Stein MR; Engl W; Sharkhawy M; Leibl H; Puck J; Rubinstein A; Kobrynski L; Gupta S; Grant AJ; Ratnayake A; Richmond WG; Church J; Yel L; Gelmont D
J Clin Immunol; 2016 Aug; 36(6):571-82. PubMed ID: 27220317
[TBL] [Abstract][Full Text] [Related]
17. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study.
Borte M; Melamed IR; Pulka G; Pyringer B; Knutsen AP; Ochs HD; Kobayashi RH; Kobayashi AL; Gupta S; Strach M; Smits W; Pituch-Noworolska A; Moy JN
J Clin Immunol; 2017 Aug; 37(6):603-612. PubMed ID: 28755067
[TBL] [Abstract][Full Text] [Related]
19. Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS).
Vultaggio A; Azzari C; Ricci S; Martire B; Palladino V; Gallo V; Pecoraro A; Pignata C; Spadaro G; Graziani S; Moschese V; Trizzino A; Boggia GM; Matucci A
J Clin Immunol; 2018 Jul; 38(5):602-609. PubMed ID: 29951948
[TBL] [Abstract][Full Text] [Related]
20. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.
Kobayashi RH; Gupta S; Melamed I; Mandujano JF; Kobayashi AL; Ritchie B; Geng B; Atkinson TP; Rehman S; Turpel-Kantor E; Litzman J
Front Immunol; 2019; 10():40. PubMed ID: 30778345
[No Abstract] [Full Text] [Related]
[Next] [New Search]
